- Home
- MRM vs APLM Comparison
MRM vs APLM Comparison
Compare MRM & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- APLM
- Stock Information
- Founded
- MRM 2000
- APLM 2016
- Country
- MRM Japan
- APLM United States
- Employees
- MRM N/A
- APLM N/A
- Industry
- MRM Other Consumer Services
- APLM Blank Checks
- Sector
- MRM Consumer Discretionary
- APLM Finance
- Exchange
- MRM Nasdaq
- APLM Nasdaq
- Market Cap
- MRM 5.9M
- APLM 6.9M
- IPO Year
- MRM 2020
- APLM N/A
- Fundamental
- Price
- MRM $1.45
- APLM $6.40
- Analyst Decision
- MRM
- APLM
- Analyst Count
- MRM 0
- APLM 0
- Target Price
- MRM N/A
- APLM N/A
- AVG Volume (30 Days)
- MRM 36.9K
- APLM 6.6K
- Earning Date
- MRM 05-20-2025
- APLM 08-13-2025
- Dividend Yield
- MRM N/A
- APLM N/A
- EPS Growth
- MRM 27.65
- APLM N/A
- EPS
- MRM 0.18
- APLM N/A
- Revenue
- MRM $52,786,758.00
- APLM $198,000.00
- Revenue This Year
- MRM N/A
- APLM $415.15
- Revenue Next Year
- MRM N/A
- APLM N/A
- P/E Ratio
- MRM $7.83
- APLM N/A
- Revenue Growth
- MRM 21.55
- APLM N/A
- 52 Week Low
- MRM $0.34
- APLM $4.47
- 52 Week High
- MRM $8.39
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- MRM 50.91
- APLM 50.58
- Support Level
- MRM $1.33
- APLM $6.21
- Resistance Level
- MRM $1.50
- APLM $6.80
- Average True Range (ATR)
- MRM 0.09
- APLM 0.49
- MACD
- MRM -0.04
- APLM 0.01
- Stochastic Oscillator
- MRM 24.32
- APLM 63.69
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.